Celltrion, Inc.

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23/06/2025			5-day change	1st Jan Change
159,000.00 ^KRW	-1.97%		-1.12%	-11.81%

06-19	Celltrion Healthcare UK Limited Opens New UK Headquarters in Uxbridge, UK	CI
06-16	Celltrion, Inc. Announces U.S. FDA Approval of Additional Presentation of Steelara®? (Ustekinumab-Stba)	CI

Celltrion Group Plans $160 Million Divestment of Primary Care Business Rights in Asia-Pacific

Published on 04/01/2024 at 03:44, updated on 04/01/2024 at 03:45

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Celltrion, Inc.

Celltrion Healthcare UK Limited Opens New UK Headquarters in Uxbridge, UK	06-19	CI
Celltrion, Inc. Announces U.S. FDA Approval of Additional Presentation of Steelara®? (Ustekinumab-Stba)	06-16	CI
South Korean Shares Slip on Profit-Booking; Korea Zinc Loses 4% on KFTC Probe	05-27	MT
Celltrion to Issue Nearly 8.5 Million Bonus Shares Amid Valuation Concerns	05-27	MT
Celltrion Inc To Issue 8.5 Million Bonus Shares	05-26	RE
US FDA Expands Interchangeable Status for Celltrion's Humira Biosimilar Yuflyma	05-22	MT
Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens	05-22	CI
S.Korean shares end higher as pharma stocks jump on government's support pledge	05-21	RE
South Korea vows more policy support, including for drugmakers, as US tariffs weigh	05-21	RE
South Korean shares rise 1% as pharmaceutical stocks jump	05-21	RE
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 3, 2025.	05-20	CI
Celltrion, Inc. announces an Equity Buyback for 649,351 shares.	05-20	CI
Celltrion, Inc. authorizes a Buyback Plan.	05-20	CI
Celltrion Inc To Buy Back 100 Billion Won Worth Shares	05-19	RE
Celltrion Chairman Says US Drug Price Reform Unlikely to Impact Business	05-16	MT
Celltrion, Inc.'s Equity Buyback announced on April 3, 2025, has closed with 631,712 shares, representing 0.29% for KRW 99,566.21 million.	05-15	CI
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-15	CI
Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	05-13	CI
South Korean shares gain over 1% on US-China trade optimism	05-12	RE
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	05-12	DJ
Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won	05-12	RE
Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®?	04-28	CI
Celltrion, Inc. announces an Equity Buyback for 631,712 shares.	04-28	CI
Celltrion, Inc. authorizes a Buyback Plan.	04-27	CI
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	04-27	CI

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,391

Sector

Biotechnology & Medical Research

Calendar

08-07 - Q2 2025 Earnings Release (Projected)

More about the company